Navigation Links
New Shire Board Member

DUBLIN, Ireland, November 2 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that Mr David Stout joined the Board as a Non Executive Director with effect from 31 October 2009.

Mr Stout has extensive pharmaceutical experience. Most recently he was President, Pharmaceutical Operations at GSK. In this position he had responsibility for pharmaceutical operations in the United States, Europe, Japan and all other International Markets. Mr Stout was also responsible for global manufacturing and global Biologics (vaccines) at GSK. Prior to that he was President of GSK's US Pharmaceuticals Business and before that SmithKline Beecham's North American Pharmaceuticals Business. Before joining SmithKline Beecham, Mr Stout worked for many years at Schering-Plough.

Mr Stout holds directorships at Allos Therapeutics, Inc, Jabil Circuit, Inc. and Airgas Inc.

Matt Emmens, Chairman of Shire commented;

"We are delighted to welcome David Stout to the Shire Board. He brings with him extensive international experience in the pharmaceutical industry, which we believe will be of great value to Shire as it continues its growth trajectory and becomes a more global company."

Notes to Editors


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:

    For further information please contact:

    Relations    Clea Rosenfeld (Rest of the World)       +44-1256-894-160
                 Eric Rojas (North America)               +1-617-551-9715
    Media        Jessica Mann (Rest of the World)         +44-1256-894-280
                 Matthew Cabrey (North America,           +1-484-595-8248
                 Specialty Pharma)
                 Jessica Cotrone (North America, HGT)     +1-617-613-4640

SOURCE Shire Plc

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Matthew “Tex” VerMilyea, PhD, ... VerMilyea will oversee all IVF lab procedures as well as continue his ... , “We traveled 7,305 miles to Auckland, New Zealand to bring home a High ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global ... and development stages of a new closed system for isolating adipose-derived stem cells. The ... vascular fraction (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
(Date:11/30/2015)... 30, 2015  Culprits beware, a University at ... Jan Halámek, is taking crime scene fingerprint identification ...   -->   --> ... --> --> Halámek and ... a straightforward concept for identifying whether a culprit ...
Breaking Biology Technology:
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... 29, 2015  Connected health pioneer, Joseph C. ... of technology-enabled health and wellness, and the business opportunities ... The Internet of Healthy Things . Long ... even existed, Dr. Kvedar, vice president, Connected Health, Partners ... delivery, moving care from the hospital or doctor,s office ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
Breaking Biology News(10 mins):